Study shows that Libtayo plus chemotherapy has lower cost and a larger effect on improving quality-adjusted life years than ...

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. My name is Tawanda, and I will be your ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo.

At this time ... Dupixent, Libtayo, and EYLEA and EYLEA HD. 2024 was also a year in which we made significant investments across our broad pipeline, which yielded notable progress across several ...

Regeneron beat Q4 estimates with $12.07 EPS and $3.79B in sales. The company announced a dividend, a $3 billion buyback, and continued R&D investments.

In the fourth quarter of 2024, Libtayo grew sales 50% to $367 million, propelling the PD-1 treatment past the blockbuster threshold for the first time. During the full year, the drug's sales reach ...

Yesterday, the clock was set at 89 seconds to midnight — the closest the world has ever been to that marker. (CNN) Property News: What falling interest rates will mean for the property market ...

Trump took his time before settling on Bessent as his nominee. He also mulled over billionaire investor John Paulson and Howard Lutnick, whom Trump tapped for commerce secretary. The treasury ...